CZ283721B6 - Purinové deriváty a jejich farmaceutické použití - Google Patents
Purinové deriváty a jejich farmaceutické použití Download PDFInfo
- Publication number
- CZ283721B6 CZ283721B6 CS913915A CS391591A CZ283721B6 CZ 283721 B6 CZ283721 B6 CZ 283721B6 CS 913915 A CS913915 A CS 913915A CS 391591 A CS391591 A CS 391591A CZ 283721 B6 CZ283721 B6 CZ 283721B6
- Authority
- CZ
- Czechia
- Prior art keywords
- acetoxy
- amino
- purine
- acetoxymethylbut
- pharmaceutical preparations
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000003612 virological effect Effects 0.000 claims abstract description 5
- -1 cyclic acetal Chemical class 0.000 claims abstract 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KXPSHSVVYGZKAV-UHFFFAOYSA-N [2-(acetyloxymethyl)-4-(2-amino-6-chloropurin-9-yl)butyl] acetate Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1Cl KXPSHSVVYGZKAV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848423833A GB8423833D0 (en) | 1984-09-20 | 1984-09-20 | Compounds |
| GB858510331A GB8510331D0 (en) | 1985-04-23 | 1985-04-23 | Compounds |
| GB858520618A GB8520618D0 (en) | 1985-08-16 | 1985-08-16 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS391591A3 CS391591A3 (en) | 1992-05-13 |
| CZ283721B6 true CZ283721B6 (cs) | 1998-06-17 |
Family
ID=27262464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS913915A CZ283721B6 (cs) | 1984-09-20 | 1991-12-19 | Purinové deriváty a jejich farmaceutické použití |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0182024B1 (en:Method) |
| JP (2) | JPS6185388A (en:Method) |
| KR (1) | KR930006349B1 (en:Method) |
| AT (1) | AT389118B (en:Method) |
| AU (1) | AU589371B2 (en:Method) |
| BG (1) | BG61493B2 (en:Method) |
| CA (1) | CA1262899A (en:Method) |
| CY (1) | CY1747A (en:Method) |
| CZ (1) | CZ283721B6 (en:Method) |
| DE (1) | DE3582399D1 (en:Method) |
| DK (1) | DK167019B1 (en:Method) |
| ES (1) | ES8703876A1 (en:Method) |
| FI (1) | FI87564C (en:Method) |
| GR (1) | GR852272B (en:Method) |
| HK (1) | HK128693A (en:Method) |
| HU (1) | HU198934B (en:Method) |
| IE (1) | IE58141B1 (en:Method) |
| MX (1) | MX165116B (en:Method) |
| MY (1) | MY102473A (en:Method) |
| NL (1) | NL960006I1 (en:Method) |
| NO (1) | NO167572C (en:Method) |
| NZ (1) | NZ213528A (en:Method) |
| PT (1) | PT81160B (en:Method) |
| WO (1) | WO1987005604A1 (en:Method) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8406538D0 (sv) | 1984-12-21 | 1984-12-21 | Astra Laekemedel Ab | Novel derivatives of purine |
| GB8628826D0 (en) * | 1986-12-02 | 1987-01-07 | Beecham Group Plc | Pharmaceutical products |
| ES2098219T3 (es) * | 1987-08-01 | 1997-05-01 | Beecham Group Plc | Compuestos de purina y su preparacion. |
| US5175288A (en) * | 1987-08-01 | 1992-12-29 | Beecham Group P.L.C. | Process for preparing purine derivatives and intermediates thereof |
| GB8817270D0 (en) * | 1988-07-20 | 1988-08-24 | Beecham Group Plc | Novel process |
| GB8817607D0 (en) * | 1988-07-23 | 1988-09-01 | Beecham Group Plc | Novel process |
| GB8822236D0 (en) * | 1988-09-21 | 1988-10-26 | Beecham Group Plc | Chemical process |
| CA2009109A1 (en) * | 1989-02-02 | 1990-08-02 | John Hannah | Antiviral acyclonucleosides and acyclonucleotides |
| JPH02247191A (ja) * | 1989-02-02 | 1990-10-02 | Merck & Co Inc | 抗レトロウイルス剤としてのプリンおよびピリミジン非環状ヌクレオシドの環状モノホスフエート類 |
| GB8904855D0 (en) * | 1989-03-03 | 1989-04-12 | Beecham Group Plc | Pharmaceutical treatment |
| GB8922076D0 (en) * | 1989-09-28 | 1989-11-15 | Beecham Group Plc | Novel process |
| GB9004647D0 (en) * | 1990-03-01 | 1990-04-25 | Beecham Group Plc | Pharmaceuticals |
| GB9102127D0 (en) * | 1991-01-31 | 1991-03-13 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9201961D0 (en) | 1992-01-30 | 1992-03-18 | Smithkline Beecham Plc | Pharmaceuticals |
| US6124304A (en) * | 1993-10-05 | 2000-09-26 | Smithkline Beecham Plc | Penciclovir for the treatment of zoster associated pain |
| IL111138A (en) * | 1993-10-05 | 1997-04-15 | Smithkline Beecham Plc | Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia |
| GB9326177D0 (en) * | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9323404D0 (en) * | 1993-11-12 | 1994-01-05 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9323403D0 (en) * | 1993-11-12 | 1994-01-05 | Smithkline Beecham Plc | Pharmaceuticals |
| US6683084B1 (en) | 1993-11-12 | 2004-01-27 | Novartis International Pharmaceutical Ltd. | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections |
| GB9402161D0 (en) | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
| GB9407698D0 (en) | 1994-04-19 | 1994-06-15 | Smithkline Beecham Plc | Pharmaceuticals |
| DE4420751A1 (de) * | 1994-06-15 | 1995-12-21 | Basf Ag | Verfahren zur Herstellung von enantiomerenreinen Lactamen |
| MX9702488A (es) * | 1994-10-05 | 1998-04-30 | Darwin Discovery Ltd | Compuestos de purina y guanina como inhibidores de pnp. |
| RU2181049C2 (ru) * | 1994-12-12 | 2002-04-10 | Новартис Интернэшнл Фармасьютикал Лтд. | Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса |
| GB9504497D0 (en) | 1995-03-07 | 1995-04-26 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9600847D0 (en) * | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
| ES2165020T3 (es) * | 1996-02-07 | 2002-03-01 | Novartis Int Pharm Ltd | Monohidrato de famciclovir. |
| US7279483B2 (en) | 1996-02-07 | 2007-10-09 | Novartis Ag | Famciclovir monohydrate |
| GB9615253D0 (en) * | 1996-07-20 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| GR1002949B (el) * | 1996-07-20 | 1998-07-29 | Smithkline Beecham P.L.C. | Φαρμακα |
| GB9615276D0 (en) * | 1996-07-20 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| CA2251481A1 (en) | 1997-11-12 | 1999-05-12 | Junichi Yasuoka | Purine derivatives having cyclopropane ring |
| GB9807116D0 (en) | 1998-04-02 | 1998-06-03 | Smithkline Beecham Plc | Novel process |
| SI20022A (sl) * | 1998-07-29 | 2000-02-29 | Kemijski inštitut | Alkilno substituirani purinovi derivati in njihova priprava |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| US20040097528A1 (en) | 2002-08-26 | 2004-05-20 | Ben-Zion Dolitzky | Crystalline solid famciclovir forms I, II, III and preparation thereof |
| ES2308136T3 (es) | 2003-01-14 | 2008-12-01 | Gilead Sciences, Inc. | Composiciones y procedimientos para la politerapia antiviral. |
| AU2006230269A1 (en) | 2005-03-30 | 2006-10-05 | Novartis Ag | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application |
| GB2426247A (en) | 2005-05-20 | 2006-11-22 | Arrow Int Ltd | Methods of preparing purine derivatives such as famciclovir |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| WO2017029298A1 (en) | 2015-08-17 | 2017-02-23 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A topical antiviral composition |
| CN108473519A (zh) * | 2015-12-08 | 2018-08-31 | 雷特罗芬公司 | 用于治疗神经疾病的环状磷酸酯和环状氨基磷酸酯 |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| WO2022060391A1 (en) | 2020-09-18 | 2022-03-24 | Halliburton Energy Services, Inc. | Non-intrusive tracking of objects in pipelines and wellbores |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0108285B1 (en) * | 1982-10-14 | 1988-04-20 | The Wellcome Foundation Limited | Antiviral purine derivatives |
| DE3485225D1 (de) * | 1983-08-18 | 1991-12-05 | Beecham Group Plc | Antivirale guanin-derivate. |
| AU577303B2 (en) * | 1983-08-18 | 1988-09-22 | Novartis International Pharmaceutical Ltd | 9-substituted-2-amino purines |
| EP0152316B1 (en) * | 1984-01-26 | 1989-07-26 | Merck & Co. Inc. | Substituted butyl guanines and their utilization in antiviral compositions |
-
1985
- 1985-09-09 EP EP85111354A patent/EP0182024B1/en not_active Expired - Lifetime
- 1985-09-09 DE DE8585111354T patent/DE3582399D1/de not_active Expired - Lifetime
- 1985-09-18 GR GR852272A patent/GR852272B/el unknown
- 1985-09-18 AU AU47560/85A patent/AU589371B2/en not_active Expired
- 1985-09-18 PT PT81160A patent/PT81160B/pt unknown
- 1985-09-18 NZ NZ213528A patent/NZ213528A/xx unknown
- 1985-09-18 DK DK424685A patent/DK167019B1/da not_active IP Right Cessation
- 1985-09-18 IE IE230785A patent/IE58141B1/en not_active IP Right Cessation
- 1985-09-18 CA CA000491028A patent/CA1262899A/en not_active Expired
- 1985-09-19 ES ES547128A patent/ES8703876A1/es not_active Expired
- 1985-09-19 JP JP60207693A patent/JPS6185388A/ja active Granted
- 1985-10-01 MX MX9010A patent/MX165116B/es unknown
-
1986
- 1986-03-17 HU HU863048A patent/HU198934B/hu unknown
- 1986-03-17 AT AT0904286A patent/AT389118B/de not_active IP Right Cessation
- 1986-03-17 WO PCT/GB1986/000153 patent/WO1987005604A1/en active IP Right Grant
- 1986-03-17 KR KR1019870701056A patent/KR930006349B1/ko not_active Expired - Lifetime
-
1987
- 1987-09-29 MY MYPI87002221A patent/MY102473A/en unknown
- 1987-11-16 FI FI875059A patent/FI87564C/fi not_active IP Right Cessation
- 1987-11-16 NO NO87874764A patent/NO167572C/no unknown
-
1991
- 1991-12-19 CZ CS913915A patent/CZ283721B6/cs not_active IP Right Cessation
-
1993
- 1993-05-07 JP JP5130044A patent/JPH0826021B2/ja not_active Expired - Lifetime
- 1993-11-10 BG BG098209A patent/BG61493B2/bg unknown
- 1993-11-18 HK HK1286/93A patent/HK128693A/en not_active IP Right Cessation
-
1994
- 1994-06-03 CY CY174794A patent/CY1747A/xx unknown
-
1996
- 1996-04-09 NL NL960006C patent/NL960006I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ283721B6 (cs) | Purinové deriváty a jejich farmaceutické použití | |
| KR0160768B1 (ko) | 제약학적 용도를 갖는 8-치환 크산틴 화합물 | |
| JP4004066B2 (ja) | プリン誘導体およびその製法 | |
| AU693079B2 (en) | Enantiomerically pure beta -D-dioxolane nucleosides with selective anti-hepatitis B virus activity | |
| DE69425574T2 (de) | L-2',3'-dideoxy-nukleosidanaloga als anti-hepatitis b-(hbv) und anti-hiv-wirkstoffe | |
| EP1165096B1 (en) | Use of cytidine derivatives for the treatment of leukaemia | |
| EP0011609B1 (en) | Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease | |
| DE2539963A1 (de) | Purinverbindungen und ihre salze, sowie verfahren zu ihrer herstellung | |
| DK154561B (da) | Analogifremgangsmaade til fremstilling af antivirale 9-substituerede 2-aminopurinderivater eller fysiologisk acceptable salte eller estere deraf | |
| JPS63239294A (ja) | 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 | |
| DE4207363A1 (de) | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung | |
| JPH04990B2 (en:Method) | ||
| JPS63297381A (ja) | ９−〔２−（ヒドロキシメチル）シクロアルキルメチル〕グアニン類 | |
| JPS6087298A (ja) | プリン及びピリミジン非環式ヌクレオシドの環状ピロホスフエート | |
| DE68923913T2 (de) | Neplanocinderivate. | |
| CA1054521A (en) | Biological materials | |
| EP0361831B1 (en) | Antiviral nucleoside combination | |
| JPS6157584A (ja) | 抗ウイルス化合物 | |
| DD210274A5 (de) | Verfahren zur herstellung von guaninderivaten | |
| JPH07502740A (ja) | 治療用ヌクレオシド | |
| EP0366385A1 (en) | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | |
| WO1995001355A1 (en) | 9-deazahypoxanthines as pnp inhibitors | |
| JPH013185A (ja) | 活性化合物、その製法及びそれを含む医薬組成物 | |
| DE3854158T2 (de) | Nucleosid-analoge. | |
| US5250688A (en) | Purine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20000920 |